MedPlus Subsidiary Faces 15-Day Drug License Suspension in Maharashtra

1 min read     Updated on 25 Sept 2025, 06:25 PM
scanx
Reviewed by
Suketu GalaScanX News Team
whatsapptwittershare
Overview

Optival Health Solutions, a subsidiary of Medplus Health Services, received a 15-day suspension order for a drug license at its Nagpur store. The suspension, issued by the Assistant Commissioner & Licensing Authority of Food & Drug Administration, Nagpur, cites a violation under the Drugs and Cosmetics Act. Medplus estimates a potential revenue loss of approximately Rs. 2.29 lakhs due to this suspension.

20350540

*this image is generated using AI for illustrative purposes only.

Medplus Health Services announced that its subsidiary, Optival Health Solutions Private Limited, has received a 15-day suspension order for a drug license at one of its stores in Maharashtra.

Suspension Details

The Assistant Commissioner & Licensing Authority of Food & Drug Administration, Nagpur, issued the suspension order for a store located in Vishwakarma Nagar, Nagpur. The order cites a violation under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

Financial Impact

Medplus Health Services estimates a potential revenue loss of approximately Rs. 2.29 lakhs due to this suspension. The company disclosed this information in compliance with SEBI regulations, specifically Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Compliance

The suspension order aligns with recent SEBI circulars, which require listed entities to disclose such regulatory actions promptly.

Company Response

Manoj Kumar Srivastava, Company Secretary & Compliance Officer of Medplus Health Services, confirmed that the details of the suspension order will be available on the company's website as well as on the websites of BSE Limited and National Stock Exchange of India Ltd.

This incident highlights the ongoing regulatory scrutiny in the pharmaceutical retail sector and the importance of maintaining compliance with drug licensing regulations.

Historical Stock Returns for Medplus Health Services

1 Day5 Days1 Month6 Months1 Year5 Years
-1.53%-6.38%-6.56%+6.97%+14.00%-29.81%
Medplus Health Services
View in Depthredirect
like16
dislike

MedPlus Subsidiary Faces 7-Day Drug License Suspension in Andhra Pradesh

1 min read     Updated on 22 Sept 2025, 07:26 PM
scanx
Reviewed by
Riya DeyScanX News Team
whatsapptwittershare
Overview

Optival Health Solutions, a subsidiary of Medplus Health Services, received a seven-day suspension order for a Drug License at one of its stores in Andhra Pradesh. The suspension, issued by the local Drug Control Administration, cites violations under the Drugs and Cosmetics Act. Medplus estimates a potential revenue loss of Rs. 1.48 lakhs due to the week-long closure. The company disclosed this information in compliance with SEBI regulations.

20095025

*this image is generated using AI for illustrative purposes only.

Medplus Health Services announced that its subsidiary, Optival Health Solutions Private Limited, has received a seven-day suspension order for a Drug License at one of its stores in Andhra Pradesh.

Suspension Details

The suspension order, issued by the Assistant Director, District Sales Licensing Authority, Drugs Control Administration, Ananthapuramu Zone-I, affects a store located on Kalyanadurgham Road in Andhra Pradesh. The order cites violations under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

Financial Impact

Medplus Health Services estimates that the week-long suspension could result in a potential revenue loss of approximately Rs. 1.48 lakhs for the company. This figure highlights the importance of regulatory compliance in the pharmaceutical retail sector.

Regulatory Disclosure

The company disclosed this information in compliance with Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure also adheres to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024.

Company Response

Manoj Kumar Srivastava, Company Secretary & Compliance Officer of Medplus Health Services, signed off on the regulatory filing. The company has stated that further details of the suspension order will be available on its official website, as well as on the websites of BSE Limited and National Stock Exchange of India Ltd.

This incident serves as a reminder of the strict regulatory environment in which pharmaceutical retailers operate and the potential consequences of non-compliance.

Historical Stock Returns for Medplus Health Services

1 Day5 Days1 Month6 Months1 Year5 Years
-1.53%-6.38%-6.56%+6.97%+14.00%-29.81%
Medplus Health Services
View in Depthredirect
like16
dislike
More News on Medplus Health Services
Explore Other Articles
786.90
-12.25
(-1.53%)